Focal Segmental Glomerulosclerosis Market to Reach $2,100.6 Million by 2035

Focal segmental glomerulosclerosis market was valued at $1,208.0 million in 2025 and is anticipated to reach $2,100.6 million by 2035, registering a CAGR of 5.8% over the forecast period from 2026 to 2035. The growth of the focal segmental glomerulosclerosis (FSGS) market is strongly linked to the increasing burden of chronic kidney disease, which expands the patient population requiring long-term pharmacological management and renal replacement therapies. According to US Centers for Disease Control and Prevention, more than 35.5 million adults in the US, or nearly 14% of the adult population, are living with chronic kidney disease, while as many as nine in ten individuals remain unaware of their condition.

Browse the full report description of “Focal Segmental Glomerulosclerosis Market Size, Share & Trends Analysis RepoBy Disease Type (Primary FSGS, Secondary FSGS), By Diagnosis (Kidney Biopsy, Blood Tests, Urine Tests, Genetic Testing) By Treatment (Pharmacological Therapy [Corticosteroids, Calcineurin Inhibitors, RAAS Inhibitors, Emerging Targeted Therapies such as Sparsentan], Dialysis, Kidney Transplant) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/focal-segmental-glomerulosclerosis-market

Early identification through blood, urine, and biopsy testing continues to improve diagnosis rates for proteinuric kidney disorders such as FSGS, supporting consistent adoption of immunosuppressive and RAAS-based therapies. Moreover, around 360 patients begin dialysis or kidney transplant treatment every day, indicating the steady progression of renal disease toward advanced stages that require ongoing treatment. In addition, national transplant statistics show 27,332 kidney transplants completed in 2023, reinforcing the long-term need for calcineurin inhibitors and corticosteroid regimens used after transplantation. These epidemiological trends create a stable clinical foundation that directly supports market expansion through sustained therapy demand and improved treatment continuity.

Key Leaders Transforming the Focal Segmental Glomerulosclerosis Market

The Key players in the focal segmental glomerulosclerosis market include Astellas Pharma Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Travere Therapeutics, Inc. These companies are advancing targeted therapies, strengthening immunosuppressive treatment options, and expanding renal research programs to improve proteinuria control and kidney function preservation. Continuous clinical development and regulatory progress are supporting the evolution of disease-specific treatment strategies within the FSGS market.

• In October 2025, Chugai Pharmaceutical completed an acquisition agreement to make Renalys Pharma a wholly owned subsidiary, gaining exclusive development and commercialization rights for sparsentan across Japan, South Korea, and Taiwan. This strategic expansion strengthens regional renal pipelines and accelerates access to targeted therapies for rare kidney diseases, including FSGS.
• In March 2025, Dimerix entered an exclusive development and commercialization agreement with Fuso Pharmaceutical Industries for its Phase III candidate DMX-200, targeting FSGS. The partnership reflects growing industry collaboration aimed at advancing disease-specific treatments and expanding late-stage pipelines.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product
  • By Form
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Astellas Pharma Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Travere Therapeutics, Inc.,, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Focal Segmental Glomerulosclerosis Market Report Segment

By Disease Type

• Primary FSGS
• Secondary FSGS

By Diagnosis

• Kidney Biopsy
• Blood Tests
• Urine Tests
• Genetic Testing

By Treatment

• Pharmacological Therapy
• Corticosteroids
• Calcineurin Inhibitors
• RAAS Inhibitors
• Dialysis
• Kidney Transplant

Global Focal Segmental Glomerulosclerosis Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/focal-segmental-glomerulosclerosis-market